These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35601972)

  • 1. First-line chemotherapeutic treatment for oligodendroglioma, WHO grade 3-PCV or temozolomide?
    van der Meulen M; Mason WP
    Neurooncol Pract; 2022 May; 9(3):163-164. PubMed ID: 35601972
    [No Abstract]   [Full Text] [Related]  

  • 2. Radiotherapy plus temozolomide or PCV in patients with anaplastic oligodendroglioma 1p19q codeleted.
    Gonzalez-Aguilar A; Reyes-Moreno I; Peiro-Osuna RP; Hernandez-Hernandez A; Gutierrez-Aceves A; Santos-Zambrano J; Guerrero-Juarez V; Lopez-Martinez M; Castro-Martinez E
    Rev Neurol; 2018 Oct; 67(8):293-297. PubMed ID: 30289152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCV chemotherapy alone for WHO grade 2 oligodendroglioma: prolonged disease control with low risk of malignant progression.
    Weller J; Katzendobler S; Karschnia P; Lietke S; Egensperger R; Thon N; Weller M; Suchorska B; Tonn JC
    J Neurooncol; 2021 Jun; 153(2):283-291. PubMed ID: 33932195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapy for the treatment of oligodendroglial tumors.
    Chinot O
    Semin Oncol; 2001 Aug; 28(4 Suppl 13):13-8. PubMed ID: 11550134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972.
    van den Bent MJ; Chinot O; Boogerd W; Bravo Marques J; Taphoorn MJ; Kros JM; van der Rijt CC; Vecht CJ; De Beule N; Baron B
    Ann Oncol; 2003 Apr; 14(4):599-602. PubMed ID: 12649108
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuro-Oncology Clinical Debate: PCV or temozolomide in combination with radiation for newly diagnosed high-grade oligodendroglioma.
    Ruff MW; Buckner JC; Johnson DR; van den Bent MJ; Geurts M
    Neurooncol Pract; 2019 Jan; 6(1):17-21. PubMed ID: 31386006
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 1p/19q loss within oligodendroglioma is predictive for response to first line temozolomide but not to salvage treatment.
    Kouwenhoven MC; Kros JM; French PJ; Biemond-ter Stege EM; Graveland WJ; Taphoorn MJ; Brandes AA; van den Bent MJ
    Eur J Cancer; 2006 Oct; 42(15):2499-503. PubMed ID: 16914310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improvement of functional outcome for patients with newly diagnosed grade 2 or 3 gliomas with co-deletion of 1p/19q - IMPROVE CODEL: the NOA-18 trial.
    Wick A; Sander A; Koch M; Bendszus M; Combs S; Haut T; Dormann A; Walter S; Pertz M; Merkle-Lock J; Selkrig N; Limprecht R; Baumann L; Kieser M; Sahm F; Schlegel U; Winkler F; Platten M; Wick W; Kessler T
    BMC Cancer; 2022 Jun; 22(1):645. PubMed ID: 35692047
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.
    Roth P; Wick W; Weller M
    Curr Treat Options Oncol; 2013 Dec; 14(4):505-13. PubMed ID: 23907441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Grade II and III Oligodendroglioma and Astrocytoma.
    van den Bent MJ; Chang SM
    Neurol Clin; 2018 Aug; 36(3):467-484. PubMed ID: 30072066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temozolomide chemotherapy in recurrent oligodendroglioma.
    van den Bent MJ; Keime-Guibert F; Brandes AA; Taphoorn MJ; Kros JM; Eskens FA; Carpentier AF
    Neurology; 2001 Jul; 57(2):340-2. PubMed ID: 11468326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early Postoperative Treatment versus Initial Observation in CNS WHO Grade 2 and 3 Oligodendroglioma: Clinical Outcomes and DNA Methylation Patterns.
    Mair MJ; Leibetseder A; Heller G; Puhr R; Tomasich E; Goldberger S; Hatziioannou T; Wöhrer A; Widhalm G; Dieckmann K; Aichholzer M; Weis S; von Oertzen T; Furtner J; Pichler J; Preusser M; Berghoff AS
    Clin Cancer Res; 2022 Oct; 28(20):4565-4573. PubMed ID: 35998208
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-grade and anaplastic oligodendroglioma.
    Van Den Bent MJ; Bromberg JE; Buckner J
    Handb Clin Neurol; 2016; 134():361-80. PubMed ID: 26948366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma.
    Tang BN; Sadeghi N; Branle F; De Witte O; Wikler D; Goldman S
    J Neurooncol; 2005 Jan; 71(2):161-8. PubMed ID: 15690133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for temozolomide.
    Rinne ML; Wen PY
    Oncology (Williston Park); 2015 Apr; 29(4):265, 275. PubMed ID: 25952491
    [No Abstract]   [Full Text] [Related]  

  • 16. Safety and efficacy of temozolomide in patients with recurrent anaplastic oligodendrogliomas after standard radiotherapy and chemotherapy.
    Chinot OL; Honore S; Dufour H; Barrie M; Figarella-Branger D; Muracciole X; Braguer D; Martin PM; Grisoli F
    J Clin Oncol; 2001 May; 19(9):2449-55. PubMed ID: 11331324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anaplastic glioma.
    Paleologos NA; Merrell RT
    Curr Treat Options Neurol; 2012 Aug; 14(4):381-90. PubMed ID: 22665140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treating anaplastic oligodendrogliomas and WHO grade 2 gliomas: PCV or temozolomide? The case for PCV.
    Levin VA
    Oncology (Williston Park); 2015 Apr; 29(4):264, 266-8. PubMed ID: 25952490
    [No Abstract]   [Full Text] [Related]  

  • 19. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas.
    Triebels VH; Taphoorn MJ; Brandes AA; Menten J; Frenay M; Tosoni A; Kros JM; Stege EB; Enting RH; Allgeier A; van Heuvel I; van den Bent MJ
    Neurology; 2004 Sep; 63(5):904-6. PubMed ID: 15365146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent developments in the molecular characterization and treatment of oligodendroglial tumors.
    van den Bent M; Chinot OL; Cairncross JG
    Neuro Oncol; 2003 Apr; 5(2):128-38. PubMed ID: 12672285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.